Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

Lancet Oncol. 2021 May;22(5):581-583. doi: 10.1016/S1470-2045(21)00155-8. Epub 2021 Apr 1.

Authors

Barliz Waissengrin¹, Abed Agbarya², Esraa Safadi³, Hagit Padova⁴, Ido Wolf⁵

Affiliations

¹ Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.
² Oncology Unit, Bnei Zion Medical Center, Haifa, Israel.
³ Sackler School of Medicine, Tel Aviv, Israel.
⁴ Patient Safety and Quality, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.
⁵ Oncology Division, Tel Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel; Sackler School of Medicine, Tel Aviv, Israel. Electronic address: idow@tlvmc.gov.il.

No abstract available

MeSH terms

BNT162 Vaccine
COVID-19 / prevention & control*
COVID-19 Vaccines / adverse effects*
Humans
Immune Checkpoint Inhibitors / therapeutic use*
Neoplasms / drug therapy*
SARS-CoV-2 / immunology*

Substances

COVID-19 Vaccines
Immune Checkpoint Inhibitors
BNT162 Vaccine